TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Narrative Exposure Therapy Compared to Treatment as Usual for Traumatized Refugees and Asylum Seekers in Mid-Norway
Brief Summary: In this study we want to compare Narrative Exposure Therapy to Treatment as Usual for traumatized refugees and asylum seekers in the Mid- Norway region. Clinicians in psychiatric outpatient clinics will deliver the two conditions to asylum seekers and refugees that qualifies for Posttraumatic Stress Disorder. We will investigate if refugees and asylum seekers will improve more with Narrative Exposure Therapy or Treatment as Usual, and if there will be any differences between improvement for asylum seekers compared to improvement for refugees with residential status.


Options:
A: Arm Label: Narrative Exposure Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy | Arm Label: treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: treatment as usual | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): Narrative Exposure Therapy | Intervention Type: BEHAVIORAL; Name: treatment as usual; Assigned to Arm(s): treatment as usual
B: Arm Label: Control - VSLA; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control - Mental Health; Type: OTHER; Interventions: Behavioral: Treatment as usual | Arm Label: Voluntary Savings/Loans Assoc; Type: EXPERIMENTAL; Interventions: Behavioral: Voluntary Savings/Loans Assoc | Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Control - Mental Health | Intervention Type: BEHAVIORAL; Name: Voluntary Savings/Loans Assoc; Assigned to Arm(s): Voluntary Savings/Loans Assoc | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy
C: Arm Label: Venlafaxine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Venlafaxine | Arm Label: Sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): Venlafaxine | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: NET | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: NET; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Exercise in Hypertension, Randomised Clinical Trial
Brief Summary: Endurance training has a documented effect on hypertension. However, only low to moderate training intensity has so far been studied. High aerobic intensity should, from physiological considerations, prove more effective in also reducing high blood pressure. The present study is a randomised comparison of high versus moderate intensity versus training in groups, and general advice on 24 hour blood pressure in hypertensives. The training period is 12 weeks, with follow-up after 1 year. Maximum oxygen uptake, quality of life, left ventricular function and blood vessel reactivity are also measured.


Options:
A: Arm Label: Stair walking; Type: EXPERIMENTAL; Interventions: Behavioral: Stair walking | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stair walking | Intervention Type: BEHAVIORAL; Name: Stair walking; Assigned to Arm(s): Control, Stair walking
B: Arm Label: Control Group; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Programme Only Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Other: Usual Care | Arm Label: Cash Incentive Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: Cash Incentives, Other: Usual Care | Arm Label: Charitable Incentive Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: Charitable Incentives, Other: Usual Care | Intervention Type: DEVICE; Name: Fitbit; Assigned to Arm(s): Cash Incentive Group, Charitable Incentive Group, Programme Only Group | Intervention Type: BEHAVIORAL; Name: Cash Incentives; Assigned to Arm(s): Cash Incentive Group | Intervention Type: BEHAVIORAL; Name: Charitable Incentives; Assigned to Arm(s): Charitable Incentive Group | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Cash Incentive Group, Charitable Incentive Group, Control Group, Programme Only Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group mediated cognitive behavioral (GMCB) sessions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions | Intervention Type: BEHAVIORAL; Name: Group mediated cognitive behavioral (GMCB) sessions; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Health education sessions; Assigned to Arm(s): 2
D: Arm Label: AIT: aerobic interval training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic interval training | Arm Label: MIT, moderate intensity training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: moderate intensity training | Arm Label: Recommendation of regular exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Recommendation of regular exercise | Intervention Type: BEHAVIORAL; Name: Aerobic interval training; Assigned to Arm(s): AIT: aerobic interval training | Intervention Type: BEHAVIORAL; Name: moderate intensity training; Assigned to Arm(s): MIT, moderate intensity training | Intervention Type: BEHAVIORAL; Name: Recommendation of regular exercise; Assigned to Arm(s): Recommendation of regular exercise

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effective Endurance Training in Metabolic Syndrome
Brief Summary: To see how fast and how much physical training can reduce risk factors related to metabolic syndrome


Options:
A: Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise
B: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Self-managed walking | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Self-managed walking; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
D: Arm Label: Physical, social and cultural activities; Type: EXPERIMENTAL; Interventions: Behavioral: Physical, social and cultural activities | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical, social and cultural activities; Assigned to Arm(s): Physical, social and cultural activities

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Eight-week, Randomized, Double-blind, Multi-center, Active-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of an Aliskiren-based Regimen Compared to a Lisinopril-based Regimen in Patients With Uncomplicated Severe Hypertension
Brief Summary: To compare the safety and efficacy of an aliskiren-based regimen to a lisinopril-based regimen in the treatment of severe hypertension


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Other: Placebo to Ramipril | Arm Label: Ramipril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Other: Placebo to Aliskiren | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: OTHER; Name: Placebo to Ramipril; Assigned to Arm(s): Aliskiren | Intervention Type: OTHER; Name: Placebo to Aliskiren; Assigned to Arm(s): Ramipril
D: Arm Label: Aliskiren 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Ramipril 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren 150 mg, Aliskiren 300 mg, Aliskiren 75 mg | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril 5 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Eight-week, Randomized, Double-blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus
Brief Summary: To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
D: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Eight-week, Randomized, Double-blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus
Brief Summary: To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus


Options:
A: Arm Label: Ramipril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Matching placebo to Aliskiren | Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Matching placebo to Ramipril | Arm Label: Placebo to Ramipril; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to Ramipril | Arm Label: Placebo to Aliskiren; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to Aliskiren | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: DRUG; Name: Matching placebo to Aliskiren; Assigned to Arm(s): Placebo to Aliskiren, Ramipril | Intervention Type: DRUG; Name: Matching placebo to Ramipril; Assigned to Arm(s): Aliskiren, Placebo to Ramipril
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
D: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Enalapril

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Arm Label: Atenolol; Type: EXPERIMENTAL; Interventions: Drug: Atenolol | Arm Label: Hydrochlorothiazide (HCTZ); Type: EXPERIMENTAL; Interventions: Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Hydrochlorothiazide (HCTZ) | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): Atenolol
B: Arm Label: Benazepril/amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Arm Label: Benazepril/hydrochlorothiazide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Intervention Type: DRUG; Name: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/hydrochlorothiazide
C: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
D: Arm Label: Chlorthalidone plus amiloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorthalidone plus amiloride | Arm Label: losartan; Type: EXPERIMENTAL; Interventions: Drug: losartan | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): losartan | Intervention Type: DRUG; Name: Chlorthalidone plus amiloride; Assigned to Arm(s): Chlorthalidone plus amiloride

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: MK0954, /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator : atenolol /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A
D: Arm Label: Chlorthalidone; Type: N/A; Interventions: Drug: Chlorthalidone | Arm Label: Amlodipine; Type: N/A; Interventions: Drug: Amlodipine | Arm Label: Lisinopril; Type: N/A; Interventions: Drug: Lisinopril | Arm Label: Doxazosin; Type: N/A; Interventions: Drug: Doxazosin | Intervention Type: DRUG; Name: Chlorthalidone; Assigned to Arm(s): Chlorthalidone | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine | Intervention Type: DRUG; Name: Doxazosin; Assigned to Arm(s): Doxazosin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: chlortalidone-amiloride; Type: EXPERIMENTAL; Interventions: Drug: Chlorthalidone plus amiloride | Intervention Type: DRUG; Name: Chlorthalidone plus amiloride; Assigned to Arm(s): chlortalidone-amiloride | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A
C: Arm Label: Valsartan 160 mg + nateglinide 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide 60 mg | Arm Label: Valsartan 160 mg + nateglinide placebo; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide placebo | Arm Label: Nateglinide 60 mg + valsartan placebo; Type: EXPERIMENTAL; Interventions: Drug: Nateglinide 60 mg + valsartan placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valsartan placebo + nateglinide placebo | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide 60 mg; Assigned to Arm(s): Valsartan 160 mg + nateglinide 60 mg | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide placebo; Assigned to Arm(s): Valsartan 160 mg + nateglinide placebo | Intervention Type: DRUG; Name: Nateglinide 60 mg + valsartan placebo; Assigned to Arm(s): Nateglinide 60 mg + valsartan placebo | Intervention Type: DRUG; Name: Valsartan placebo + nateglinide placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A

Answer: D